Clinical trials
Alzheimer clinical trials
Below are recruiting alzheimer clinical trials, each written for real people, not researchers. We’re tracking 622 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07324161Recruiting
Magnetic Brain Stimulation for Alzheimer's Disease
This trial tests whether a non-invasive magnetic brain stimulation treatment (TMS) can help people with mild to moderate Alzheimer's disease. You would receive the treatment and be monitored for safety and benefit.
Fuzhou, FujianAges 50–90 - NCT06803823RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's
This study tests an experimental drug, ONO-2020, to see if it can help reduce agitation in people with Alzheimer's disease. Agitation can include restlessness, pacing, or verbal outbursts, and this trial aims to find a new treatment option.
AichiAges 55–90 - NCT06918145Enrolling by invitation
LVA surgery for Alzheimer's disease
This study tests a surgery called lymphaticovenous anastomosis (LVA) as a possible treatment for Alzheimer's disease. The surgery connects tiny lymph vessels to veins to help clear waste from the brain.
Beijing, Beijing MunicipalityAges 50–85 - NCT07457125RecruitingPhase 1/Phase 2
Exosome therapy for mild to moderate Alzheimer's disease
This trial tests a new drug made from stem cell exosomes (CB-Exo-A600) to see if it can help people with mild to moderate Alzheimer's disease. It aims to slow down symptoms and improve quality of life.
BeijingAges 50 years+ - NCT06651567RecruitingPhase 2
Study of ITI-1284 for agitation in Alzheimer's
This trial tests an experimental drug called ITI-1284 to see if it can reduce agitation in people with Alzheimer's disease. It may help if you or your loved one experiences significant agitation related to Alzheimer's.
Anaheim, CaliforniaAges 55 years+ - NCT06540833RecruitingPhase 2
Study of ITI-1284 for psychosis in Alzheimer's disease
This trial tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis (hallucinations or delusions) in people with Alzheimer's disease. It may be an option for patients who have both Alzheimer's and related psychotic symptoms.
Anaheim, CaliforniaAges 55 years+ - NCT05511363RecruitingPhase 3
KarXT trial for Alzheimer’s psychosis symptoms
This Phase 3 trial tests whether KarXT can reduce hallucinations or delusions in people with Alzheimer’s disease. It also studies the medicine’s safety to see how well it’s tolerated during the study.
Homewood, AlabamaAges 55–90 - NCT07284472RecruitingPhase 2/Phase 3
Testing drugs for agitation in Alzheimer's disease
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
Murrieta, CaliforniaAges 55–90 - NCT06230783Recruiting
Speech test for early Alzheimer's detection
This trial uses speech pattern analysis to detect early signs of Alzheimer's. If you're already in a Wisconsin Alzheimer's study, you may help test if your voice can reveal memory changes.
Madison, WisconsinAges 40–80 - NCT07399171RecruitingPhase 2
Testing HT-4253 to prevent Alzheimer's in APOE4 carriers
This trial tests an experimental drug called HT-4253 to see if it can prevent Alzheimer's disease in people who are at higher genetic risk (carry the APOE4 gene) and have early signs of amyloid buildup in the brain. If you qualify, you would take the drug or a placebo and be monitored over time.
Abu Dhabi, Abu Dhabi EmirateAges 50–75 - NCT07153848Recruiting
Lecanemab treatment for early Alzheimer's disease
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
Hangzhou, ZhejiangAges 45–85 - NCT07632755Recruiting
Memory Training Using Movement for Early Alzheimer's Disease
This study tests whether learning memory strategies through physical movement and motor activities can help people with early Alzheimer's disease improve their memory. Researchers will compare people with early Alzheimer's to healthy older adults to see if this approach is effective.
GrenobleAges 60 years+ - NCT07732842Recruiting
Understanding Repetitive Behaviors in Alzheimer's Disease
This study looks at repetitive behaviors (like pacing, tapping, or repeating words) in people with Alzheimer's disease. They want to understand these behaviors better, which could help improve care and treatment.
Limoges, New AquitaineAges 18 years+ - NCT07477431RecruitingPhase 2
Testing levetiracetam for those at risk of Alzheimer's
This trial tests if a medication called levetiracetam (a drug usually used for seizures) can help protect memory in people who are at higher risk for Alzheimer's but do not yet have memory problems. It involves brain scans and cognitive tests to see if the drug can reduce overactive brain activity linked to memory loss.
Toronto, OntarioAges 55–85 - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Chandler, ArizonaAges 55–90 - NCT07234942RecruitingPhase 1
Safety study of RO7812653 for early Alzheimer's disease
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
Toronto, OntarioAges 50–75 - NCT06887192RecruitingPhase 2
Testing ML-007C-MA for Alzheimer's Psychosis
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
Phoenix, ArizonaAges 55–90 - NCT07731191Recruiting
Digital tools to predict Alzheimer's risk factors
This study uses smartphone tools to track early signs of Alzheimer's by analyzing risk factors. It is for people with mild cognitive issues (MCI) or subjective cognitive decline (SCD) who do not have dementia.
Brescia, BSAges 18 years+ - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Chandler, ArizonaAges 55–90 - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06862960RecruitingPhase 2
Ozanimod for moderate Alzheimer's disease
This trial tests whether a daily pill called ozanimod can help people with moderate Alzheimer's disease. The study monitors changes in thinking and memory over time and requires a study partner who can join visits.
Fuzhou, FujianAges 55–80 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95
Hear when a new Alzheimer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer?
- Yes. Clin2 currently lists 622 recruiting alzheimer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.